Overview

A Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mutiple Ocular Administrations in Healthy Korean and Caucasian Volunteers

Status:
Completed
Trial end date:
2020-07-17
Target enrollment:
Participant gender:
Summary
This study is a randomized, double-blind, placebo-controlled phase 1 clinical trial to evaluate the safety, tolerability and pharmacokinetic characteristics of GLH8NDE after single and multiple ocular administrations in healthy Korean and Caucasian volunteers
Phase:
Phase 1
Details
Lead Sponsor:
GL Pharm Tech Corporation